Literature DB >> 19450644

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Lindvi Gudmundsdotter1, Charlotta Nilsson, Andreas Brave, Bo Hejdeman, Patricia Earl, Bernard Moss, Merlin Robb, Josephine Cox, Nelson Michael, Mary Marovich, Gunnel Biberfeld, Eric Sandström, Britta Wahren.   

Abstract

The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450644      PMCID: PMC4788966          DOI: 10.1016/j.vaccine.2009.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

Authors:  Harriet L Robinson; Sunita Sharma; Jun Zhao; Sunil Kannanganat; Lilin Lai; Lakshmi Chennareddi; Tianwei Yu; David C Montefiori; Rama Rao Amara; Linda S Wyatt; Bernard Moss
Journal:  AIDS Res Hum Retroviruses       Date:  2007-12       Impact factor: 2.205

2.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

Authors:  T J Blanchard; A Alcami; P Andrea; G L Smith
Journal:  J Gen Virol       Date:  1998-05       Impact factor: 3.891

3.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

4.  Epitope mapping of the HIV-1 gag region with monoclonal antibodies.

Authors:  J Hinkula; J Rosen; V A Sundqvist; T Stigbrand; B Wahren
Journal:  Mol Immunol       Date:  1990-05       Impact factor: 4.407

5.  A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

Authors:  Andreas Bråve; Andreas Boberg; Lindvi Gudmundsdotter; Erik Rollman; Kristian Hallermalm; Karl Ljungberg; Pontus Blomberg; Richard Stout; Staffan Paulie; Eric Sandström; Gunnel Biberfeld; Patricia Earl; Bernard Moss; Josephine H Cox; Britta Wahren
Journal:  Mol Ther       Date:  2007-06-19       Impact factor: 11.454

Review 6.  Biology of immune responses to vaccines in elderly persons.

Authors:  Birgit Weinberger; Dietmar Herndler-Brandstetter; Angelika Schwanninger; Daniela Weiskopf; Beatrix Grubeck-Loebenstein
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

7.  Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Authors:  Antonio Cosma; Silja Bühler; Rashmi Nagaraj; Caroline Staib; Anna-Lena Hammarin; Britta Wahren; Frank D Goebel; Volker Erfle; Gerd Sutter
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

8.  Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Authors:  Vasee S Moorthy; Egeruan B Imoukhuede; Sheila Keating; Margaret Pinder; Daniel Webster; Michael A Skinner; Sarah C Gilbert; Gijs Walraven; Adrian V S Hill
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

9.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  37 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 3.  Development of Vaccines for Chikungunya Fever.

Authors:  Jesse H Erasmus; Shannan L Rossi; Scott C Weaver
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 5.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

6.  Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Authors:  Charlotta Nilsson; Karina Godoy-Ramirez; Bo Hejdeman; Andreas Bråve; Lindvi Gudmundsdotter; David Hallengärd; Jeffrey R Currier; Lindsay Wieczorek; Klara Hasselrot; Patricia L Earl; Victoria R Polonis; Mary A Marovich; Merlin L Robb; Eric Sandström; Britta Wahren; Gunnel Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-15       Impact factor: 2.205

Review 7.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

8.  Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Authors:  Jeffrey R Currier; Viseth Ngauy; Mark S de Souza; Silvia Ratto-Kim; Josephine H Cox; Victoria R Polonis; Patricia Earl; Bernard Moss; Sheila Peel; Bonnie Slike; Somchai Sriplienchan; Prasert Thongcharoen; Robert M Paris; Merlin L Robb; Jerome Kim; Nelson L Michael; Mary A Marovich
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

Review 10.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.